Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

28 July 2014: Clinical Research  

A Cross-Sectional Study of the Relationship Between Serum Liver Enzymes Level and the Incidence of Impaired Fasting Glucose in Males and Females

Guangming Qin ABCDE , Lihong Lu BCDE , Yufei Xiao BCF , Yimiao Zhu EF , Wensheng Pan ABEG , Xiang Xu BG , Shengrong Shen AF , Undurti N. Das ADE

DOI: 10.12659/MSM.890698

Med Sci Monit 2014; 20:1319-1325

0 Comments

Abstract

BACKGROUND: The aim of this study was to investigate the possible correlation between levels of serum liver enzymes and impaired fasting glucose (IFG) in Chinese adults and to provide a new perspective for the prevention of pre-diabetes.

MATERIAL AND METHODS: Serum liver enzymes of the samples including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and g-glutamyl transferase (GGT), as well as plasma glucose, blood lipids, and insulin, were measured. The cumulative incidences of IFG between different quartiles of liver enzymes were compared by the chi-square test. A logistic regression model (binary regression) was used to calculate the odds ratio (OR) of IFG with 95% confidence interval (95% CI).

RESULTS: The total incidence of IFG was 20.3% and the cumulative incidence of IFG was higher in men compared to women. In both sexes, IFG is more prevalent in higher quartiles of liver enzymes. After adjusting for age, BMI, blood pressure, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC), the cumulative incidences of IFG were significantly higher in the highest quartiles of liver enzymes than in the lowest quartiles. A significantly higher cumulative incidence of IFG was found in the highest GGT quartile than in the lowest quartile for woman.

CONCLUSIONS: The results of this study suggest that serum liver enzymes are related to the risk of IFG in Chinese adults. We infer that preserving the hepatic function may be an efficient way to prevent the development of IFG, especially in males.

Keywords: Alanine Transaminase - blood, Aspartate Aminotransferases - blood, China - epidemiology, Cross-Sectional Studies, Enzymes - blood, Incidence, Insulin - blood, Lipids - blood, Liver - enzymology, Logistic Models, Odds Ratio, Prediabetic State - prevention & control

Background

The liver is the site of glycogen synthesis, glyconeogenesis, and insulin degradation; thus, the liver plays an important role in the homeostasis of plasma glucose. Change in the plasma levels of hepatic enzymes is an index of hepatobiliary system dysfunction. However, enhanced plasma levels of liver enzymes serum alanine aminotransferase (ALT) [1–3], aspartate aminotransferase (AST) [4], and γ-glutamyltransferase (GGT) [5–8] might also serve as biological markers of type 2 diabetes mellitus (DM). Patients with impaired fasting glucose (IFG) are regarded as being prediabetic, and prevention during this period can decrease the incidence of DM [9]. Several studies showed that IFG might be more prevalent in men than in women, although the reasons for this difference are poorly understood [10,11]. Hence, we investigated the possible relationship between IFG and liver enzymes in both males and females in a large sample to gain insights into sex difference and its implications for pre-diabetes.

Material and Methods

SUBJECTS:

This was as a cross-sectional study of 3373 patients from Zhejiang Province who underwent physical examination in the International Health Center, Second Affiliated Hospital, School of Medicine, Zhejiang University from April 2011 to September 2011.

Inclusion criteria were healthy people aged 20–80 years. Subjects who had liver diseases such as fatty liver, chronic viral hepatitis, autoimmune liver diseases, drug-induced liver injury, and genetic liver disease, and those with hypertension, DM, and alcoholism, coronary heart disease, cancer, severe mental disorders, chronic kidney disease, pregnancy, and glucocorticoid therapy were excluded from the study. We also excluded subjects with lack of complete information of medical examination diagnosis.

A total of 2775 healthy subjects were recruited (age range 20–80 years; 1762 men, 1013 women) in this study.

METHODS:

After fasting for 12 h, patients underwent a physical examination during the hours of 7:30–9:30 AM in the medical center. Anthropometric indices, including height, weight, and body mass index (BMI), were measured and calculated (BMI = weight (kg)/height (m2). The systolic and diastolic blood pressures of the right arm were measured after a 5-min rest in sitting position. Blood pressure was measured using an automated device (Omron 711, USA) and the mean of 2 consecutive blood pressure measurements was recorded. Venous blood was collected in vacuum BD tubes (BD, USA) and serum was separated (3000 rpm/15 min) within 1 h. Laboratory parameters were measured to complete the analysis within 4 h in the Clinical Laboratory Center, Second Affiliated Hospital, School of Medicine, Zhejiang University.

Laboratory tests, including fasting plasma glucose (FPG), ALT, AST, GGT, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and fasting insulin. FPG were measured by the hexokinase (HK) method, ALT by the IFCC Reference method with P-5-P, AST by the IFCC Reference method with P-5-P, GGT by the modified SZASZ method, TC by the cholesterol oxidase-peroxidase method (CHO-POD), TG by the glycerol phosphate oxidase-peroxidase method, HDL-C by the direct method-surfactant clearance method, LDL-C by the direct method-selected inhibitor method, using a BECKMAN COULTER AU5400 Analyzer, respectively. fasting insulin were measured by direct chemical luminescence method using with SIEMENS ADVIA CENTAUR XP Analyzer.

IFG [10] was defined as 5.6 mmol/L to 6.9 mmol/L fasting plasma glucose (FPG) according to the American Diabetes Association (ADA). Insulin resistance index (HOMA-IR) and insulin secretion index (HOMA-β) were calculated based on the HOMA model: HOMA-IR = (FPG × FINS)/22.5; HOMA-β = 20 × FINS/(FPG-3.5).

STATISTICAL ANALYSIS:

The statistical analysis was performed using PASW Statistics 18.0. The TG, ALT, AST and GGT measurements generally show skewed distribution, so we analyzed these parameters after log transformation. Categorical variables were compared by the χ2 test, and continuous variables by the T test. Logistic regression analysis was performed to evaluate the relationship between serum liver enzymes level and the incidence of impaired fasting glucose. P<0.05 was considered statistically significant.

Results

CLINICAL CHARACTERISTICS OF THE STUDY SUBJECTS:

Of 2775 subjects studied, 20.3% (562/2775) were found to have IFG. The incidence of IFG in males was 23.6% (415/1762), which was significantly higher (χ2=32.6, P<0.001) than 14.5% (147/1013) in females. Other parameters that showed sex differences are presented in Table 1. The average age of the 2 groups did not show any significant difference. The mean value of systolic and diastolic blood pressures, FPG, BMI, TC, LDL-C, TG, AST, and ALT were higher in males compared to females, except for HDL-C levels, which were lower in males.

HOMA-IR AND HOMA-β AND LIVER ENZYMES:

We compared the relationship among HOMA-IR and HOMA-β in subjects of each sex with different levels of liver enzymes. These results (Table 2) revealed that there are significant differences (P<0.01) among the subgroups, except for the HOMA-IR and HOMA-β, in which there were different levels of AST in females.

QUARTILES OF EACH LIVER ENZYME AND INCIDENCE ANALYSIS OF IMPAIRED FASTING GLUCOSE:

Subjects of each sex are divided into 3 groups according to the differences in the levels of liver enzymes, and then into quartiles of the normal range of each according to their serum concentrations. Comparison of the results of different subgroups showed that the frequency of IFG increased with elevation in liver enzymes, as depicted in Figure 1. For example, in males the incidence of IFG was higher in those with ALT of the fourth quartile than that of the first quartile, while that of the second, third, and fourth quartile were higher than the first one in females. On the other hand, the third and fourth quartiles of AST showed a higher incidence of IFG compared to the first quartile in males; while in females, the highest quartile AST group had a higher incidence of IFG compared to the lowest quartile. With regard to GGT in males, the third and fourth quartile had higher incidence of IFG compared to the first quartile; while in females, the odds of the IFG increased in the second, third, and fourth quartile subgroups.

THE LOGISTIC REGRESSION ANALYSES:

Logistic regression analyses showed that increased levels of hepatic enzymes might be a significant predictor of IFG. We evolved a model of logistic regression wherein subjects with normal glucose tolerance (NGT) are valued as 0, and those with IFG as 1, and considering quartiles of the levels of different liver enzymes as independent variables, and fasting plasma glucose as the dependent variable. The results, presented in Table 3, suggest that after the adjustment for age, data of the male subjects showed that the risk of having IFG in the highest quartile of AST, ALT, and GGT was significantly greater than those in the lowest quartile (OR for ALT: 2.29, 95% CI: 1.67~3.12; OR for AST: 1.93, 95% CI: 1.43~2.60; OR for GGT: 3.19, 95% CI: 2.31~4.40). Similar statistical analysis performed in the females revealed that there was a significant correlation between the levels of liver enzymes and the incidence of IFG for the GGT group (OR for GGT: 3.63, 95% CI: 2.01~6.56), but not for ALT and AST enzymes. Further logistic regression analysis (after adjusting for variables such as blood pressure, blood lipids, and BMI) showed that the correlation between the liver enzymes and IFG was still significant (Males: OR for ALT: 1.52, 95% CI: 1.07~2.15; OR for AST: 1.51, 95% CI: 1.09~2.08; OR for GGT: 2.38, 95% CI: 1.66~3.41; Females: OR for GGT: 2.93, 95% CI: 1.58~5.43).

Discussion

Pre-diabetes is a state in which carbohydrate metabolism is mildly abnormal, the plasma glucose is slightly above the normal range, and other criteria indicating the presence of diabetes mellitus are absent. The American Diabetes Association (ADA) considers that prediabetes is a high-risk factor for the development of DM [12,13]. There are 2 forms of pre-diabetes: impaired fasting glucose (IFG) and impaired glucose intolerance. A worldwide epidemiological study showed that the incidence of both prediabetes and type 2 diabetes mellitus are increasing rapidly [14]. A report from the American National Health and Nutrition Examination Survey (NHANES) showed that 79 000 000 persons were in the prediabetic state by 2010 [15]. A large study performed in China revealed that the incidence of IFG among those who were 40–75 years old with hypertension is 14.1% [16]. As per the statistics presented by ADA, it was opined that 70% of prediabetic patients eventually develop DM, and this rate was found to be more than 90% in China [17]. A prospective study in 2007 reported that 6–9% of those with IFG developed DM, and 15–19% of those with both IFG with IGT eventually develop DM [18], although this rate of conversion from prediabetes to DM varies depending on race [19,20]. Since pre-diabetes is reversible, modification of the life-style factors and medication could revert plasma glucose to normal and thus significantly lower morbidity due to DM [9,21–24]. It is estimated that in China, 148 million people have prediabetes. Hence, it is important to detect factors that could predispose to the development of pre-diabetes and accordingly develop preventive strategies. The liver plays a significant role in the metabolism of glycogen, lipids, and protein and is responsible for the carbohydrate metabolism, including gluconeogenesis, glycogenesis, and the breakdown of the insulin. Thus, liver dysfunction could influence plasma glucose regulation. Several studies revealed liver enzymes are not only markers of liver function, but also could serve as a predictive index of DM [1–8]. The reported correlation between fasting glucose and fasting insulin levels [25,26] suggest that elevated blood glucose is associated with insulin resistance. Therefore, levels of liver enzymes could be interpreted to detect a dysfunction of insulin secretion and breakdown [27]. The results of the present study indicate that such as association between the levels of liver enzymes and plasma glucose does indeed exist.

Conclusions

A number of studies have also revealed that IFG could be related to sex, age, and BMI. The risk of IFG increases with age [15,28]. Subjects with high BMI are likely to be obese, with fat deposition in various organs, including the liver, have hyperlipidemia, and suffer from impaired insulin sensitivity that could eventually lead to β islet cell dysfunction and consequent elevation of plasma glucose [29,30]. This seems to be more likely in males. The much weaker correlation between levels of liver enzymes and IFG in females could be attributed to the stimulatory action of estrogen on insulin secretion [31]. In conclusion, our study shows that IFG can be related to the levels of hepatic enzymes; hence, efforts made to improve liver function to normal could prevent diabetes, especially in males.

References

1. Sattar N, Scherbakova O, Ford I, Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study: Diabetes, 2004; 53; 2855-60, pmid: 15504965

2. Doi Y, Kubo M, Yonemoto K, Liver enzymes as a predictor for incident diabetes in a Japanese population: the hisayama study: Obesity, 2007; 15; 1841-50, pmid: 17636103

3. Fraser A, Harris R, Sattar N, Alanine aminotransferace, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis: Diabetes Care, 2009; 32; 741-50, pmid: 19131466

4. Nannipieri M, Gonzales C, Baldi S, Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study: Diabetes Care, 2005; 28; 1757-62, pmid: 15983331

5. Nakanishi N, Suzuki K, Tatara K, Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men: Diabetes Care, 2004; 27; 1427-32, pmid: 15161799

6. Lee DH, Silventoinen K, Jacobs DR, Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women: J Clin Endocrinol Metab, 2004; 89; 5410-14, pmid: 15531490

7. André P, Balkau B, Vol SDESIR Study Group, Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation definition) in the middle-aged men and women: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort: Diabetes Care, 2007; 30; 2355-61, pmid: 17586745

8. Fujita M, Ueno K, Hata A, Association of gamma-glutamyltransferase with incidence of type 2 diabetes in Japan: Exp Biol Med, 2010; 235; 335-41

9. Diabetes Prevention Program Research Group, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study: Lancet, 2009; 374; 1677-86, pmid: 19878986

10. Tabák AG, Herder C, Rathmann W, Prediabetes: a high-risk state for diabetes development: Lancet, 2012; 379; 2279-90, pmid: 22683128

11. Yang W, Lu J, Weng J, Prevalence of diabetes among men and women in China: N Engl J Med, 2010; 362; 1090-101, pmid: 20335585

12. WHO, International Diabetes Foundation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation, 2006, Geneva, World Health Organization

13. International Expert Committee, International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes: Diabetes Care, 2009; 32; 1327-34, pmid: 19502545

14. Danaei G, Finucane MM, Lu Y, National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants: Lancet, 2011; 378; 31-40, pmid: 21705069

15. Centers for Disease Control and Prevention: National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011, 2011, Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention

16. Qin X, Li J, Zhang Y, Prevalence and Associated Factors of Diabetes and Impaired Fasting Glucose in Chinese Hypertensive Adults Aged 45 to 75 Years: PLOS one, 2012; 7; e42538, pmid: 22880024

17. Li G, Zhang P, Wang J, The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study: Lancet, 2008; 371; 1783-89, pmid: 18502303

18. Gerstein HC, Santaguida P, Raina P, Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies: Diabetes Res Clin Pract, 2007; 78; 305-12, pmid: 17601626

19. Yeboah J, Bertoni AG, Herrington DM, Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis): J Am Coll Cardiol, 2011; 58; 140-46, pmid: 21718910

20. Heianza Y, Hara S, Arase Y, HbA1c 5.7–6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study: Lancet, 2011; 378; 147-55, pmid: 21705064

21. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial: Lancet, 2006; 368; 1096-105, pmid: 16997664

22. Knowler WC, Barrett-Connor E, Fowler SEfor the Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin: N Engl J Med, 2002; 346; 393-403, pmid: 11832527

23. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L, XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients: Diabetes Care, 2004; 27; 155-61, pmid: 14693982

24. Tuomilehto J, Lindström J, Eriksson JGfor the Finnish Diabetes Prevention Study Group, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance: N Engl J Med, 2001; 344; 1343-50, pmid: 11333990

25. Ferrannini E, Gastaldelli A, Iozzo P, Pathophysiology of prediabetes: Med Clin North Am, 2011; 95; 327-39, pmid: 21281836

26. DeFronzo RA, Abdul-Ghani MA, Preservation of beta-cell function: the key to diabetes prevention: J Clin Endocrinol Metab, 2011; 96; 2354-66, pmid: 21697254

27. Bonnet F, Pierre-Henri D, Gastaldelli Afor the RISC Study Group, Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women: Diabetes, 2011; 60; 1660-67, pmid: 21521874

28. Cowie CC, Rust KF, Ford ES, Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006: Diabetes Care, 2009; 32; 287-94, pmid: 19017771

29. Schneider HJ, Friedrich N, Klotsehe J, The predictive value of different measures of obesity for incident cardiovascular events and mortality: J Clin Endocrinol Metab, 2010; 95; 1777-85, pmid: 20130075

30. Tabák AG, Jokela M, Akbaraly TN, Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study: Lancet, 2009; 373; 2215-21, pmid: 19515410

31. Gao J, He J, Shi X, Sex-specific effect estrogen sulfotransferase on mouse of type 2 diabetes: Diabetes, 2012; 61; 1543-51, pmid: 22438574

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750